2018-06-09 -   A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. British Journal of Clinical Biology 

2018-03-20 -  Roche Sees « New Front in Critical Care Medicine » With CDx Deal Aimed at Septic Shock. GenomeWeb 

2018-01-19 -  Targeted endothelial gene deletion of Triggering Receptor Expressed on Myeloid cells-1 protects mice during septic shock. Cardiovasc Res(PMID 29361046) 

2018-01-18 - Martin Koch joins Inotrem as Chief Operating Officer   french or english

2017-11-15 - Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock   french or english

2017-11-10 - Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test   french or english

2017-09-11 - Inotrem announces new preclinical data supporting its lead compound’s (LR12) positive role on vascular dysfunction during septic shock   french or english

2017-08-03 -  TREM-1 SNP rs2234246 regulates TREM-1 protein and mRNA levels and is associated with plasma levels of L-selectin. PLoS ONE(PMID 28771614) 

2017-07-27 - Triggering Receptor Expressed on Myeloid cells-1: a new player in platelet aggregation. Thrombosis and Haemostasis(PMID 28837205) 

2017-05-01 - LR12-peptide quantitation in whole blood by RP-HPLC and intrinsic fluorescence detection: Validation and pharmacokinetic study. Biomedical Chromatography(PMID 27790740) 

2017-02-27 - TREM-1 and its potential ligands in non-infectious diseases: from biology to clinical perspectives. Pharmacological Research  (PMID 28245991) 

2016-12-27 - Genetic and Pharmacological Inhibition of TREM-1 Limits the Development of Experimental Atherosclerosis. Journal of the American College of Cardiology. Inotrem collaborated in this study with Pr Hafid Ait Oufella from team 5 of the the Paris Cardiovascular Research Center (PARCC) to demonstrate the role of TREM-1 in the development of atherosclerosis. (PMID 28007141) 

2016-09-13 - Inotrem successfully completes its first phase I clinical trial with Motrem, a TREM-1 pathway modulator for the treatment of septic shock.

2015-10-30 - The Triggering Receptor Expressed on Myeloid cells-1: A new player during acute myocardial infarction. Pharmacological Research (PMID: 26318764) 

2015-06-20 - Pharmacological inhibition of the triggering receptor expressed on myeloid cells-1 limits reperfusion injury in a porcine model of myocardial infarction. ESC Heart Failure.

2015-05-22 - TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circulation Research. Inotrem published here new results demonstrating the role of TREM-1 during the pathophysiology of acute myocardial infarction. We are really proud of this disruptive paper showing for the first time the role of TREM-1 in cardiovascular setting (PMID 25840803) 

2014-04-15 - Attenuation of responses to endotoxin by the triggering receptor expressed on myeloid cells-1 inhibitor LR12 in nonhuman primate. Anesthesiology (PMID 24270127) 

2014-02-24 - Inotrem Raises €18 million to Develop Innovative Sepsis Treatments in a Series A Financing Co-led by Edmond de Rothschild Investment Partners and Sofinnova Partners.

2013-02-15 - Effects of a TREM-like transcript 1-derived peptide during hypodynamic septic shock in pigs. Shock(PMID: 23324887) 

2012-06-01 - Soluble TREM-like transcript-1 regulates leukocyte activation and controls microbial sepsis. The Journal of Immunology(PMID 22551551) 

2010-07-20 - Triggering receptor expressed on myeloid cells-1 as a new therapeutic target during inflammatory diseases. Self/Non-Self(PMID 21487478)